Avadel Pharmaceuticals PLC
AVDL18.830USD
+0.130+0.70%
Close 11/11, 16:00（ET）Quotes delayed by 15 min
1.83BMarket Cap
LossP/E TTM
More Details of Avadel Pharmaceuticals PLC Company
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME and MEDUSA. Its MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Avadel Pharmaceuticals PLC Info
Ticker SymbolAVDL
Company nameAvadel Pharmaceuticals PLC
IPO dateJan 16, 1952
CEOMr. Gregory J. (Greg) Divis, Jr.
Number of employees188
Security typeOrdinary Share
Fiscal year-endJan 16
AddressBlock 10-1 Blanchardstown Corporate Park
CityDUBLIN
Stock exchangeNASDAQ Global Market Consolidated
CountryIreland
Postal code15
Phone35319015201
Websitehttps://www.avadel.com/
Ticker SymbolAVDL
IPO dateJan 16, 1952
CEOMr. Gregory J. (Greg) Divis, Jr.
Company Executives of Avadel Pharmaceuticals PLC
Name
Name/Position
Position
Shareholding
Change
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
+5.27%
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
+10.57%
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
89.03K
+14.10%
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
87.80K
-12.55%
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
+16.20%
Ms. Susan Rodriguez
Ms. Susan Rodriguez
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Jerad Seurer
Mr. Jerad Seurer
General Counsel and Corporate Secretary
General Counsel and Corporate Secretary
--
--
Mr. Gregory J. (Greg) Divis, Jr.
Mr. Gregory J. (Greg) Divis, Jr.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Naseem Amin, M.D.
Dr. Naseem Amin, M.D.
Independent Director
Independent Director
--
--
Ms. Courtney Turiano
Ms. Courtney Turiano
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Eric J. Ende, M.D.
Dr. Eric J. Ende, M.D.
Independent Director
Independent Director
219.90K
+5.27%
Mr. Peter J. Thornton
Mr. Peter J. Thornton
Independent Director
Independent Director
115.06K
+10.57%
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Dr. Mark Anthony Mccamish, M.D., Ph.D.
Independent Director
Independent Director
89.03K
+14.10%
Mr. Thomas S. Mchugh
Mr. Thomas S. Mchugh
Chief Financial Officer
Chief Financial Officer
87.80K
-12.55%
Ms. Linda S. Palczuk
Ms. Linda S. Palczuk
Independent Director
Independent Director
78.90K
+16.20%
Ms. Susan Rodriguez
Ms. Susan Rodriguez
Chief Operating Officer
Chief Operating Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Mar 3
Currency: USDUpdated: Mon, Mar 3
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
By RegionUSD
Name
Revenue
Proportion
United States
22.33M
100.00%
Ireland
0.00
0.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Vazculep
10.43M
46.70%
Akovaz
9.54M
42.74%
Bloxiverz
2.20M
9.85%
Other
159.00K
0.71%
Shareholding Stats
Updated: Tue, Nov 11
Updated: Tue, Nov 11
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
11.40%
Brandes Investment Partners, L.P.
6.64%
Two Seas Capital LP
6.30%
BlackRock Institutional Trust Company, N.A.
6.12%
The Vanguard Group, Inc.
5.66%
Other
63.88%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
11.40%
Brandes Investment Partners, L.P.
6.64%
Two Seas Capital LP
6.30%
BlackRock Institutional Trust Company, N.A.
6.12%
The Vanguard Group, Inc.
5.66%
Other
63.88%
Shareholder Types
Shareholders
Proportion
Investment Advisor
31.44%
Investment Advisor/Hedge Fund
29.01%
Hedge Fund
24.24%
Individual Investor
4.79%
Venture Capital
3.44%
Research Firm
1.32%
Pension Fund
0.51%
Bank and Trust
0.36%
Insurance Company
0.03%
Other
4.85%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
382
84.18M
86.25%
-22.86M
2025Q2
375
87.44M
90.23%
-20.44M
2025Q1
377
85.31M
88.05%
-24.78M
2024Q4
354
86.56M
89.59%
-16.46M
2024Q3
334
81.87M
84.98%
-15.41M
2024Q2
299
81.11M
84.30%
-2.77M
2024Q1
258
76.98M
80.25%
+5.42M
2023Q4
226
62.92M
70.15%
-3.93M
2023Q3
220
60.11M
69.62%
-5.86M
2023Q2
213
57.67M
66.98%
-1.24M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
11.13M
11.46%
-2.46M
-18.10%
Jun 30, 2025
Brandes Investment Partners, L.P.
6.49M
6.68%
+820.47K
+14.48%
Jun 30, 2025
Two Seas Capital LP
6.16M
6.34%
+1.21M
+24.43%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
5.98M
6.16%
+1.29M
+27.56%
Jun 30, 2025
The Vanguard Group, Inc.
5.54M
5.71%
+1.66M
+42.73%
Jun 30, 2025
Tontine Asset Management, LLC
5.18M
5.33%
-950.54K
-15.51%
Jun 30, 2025
Polar Capital LLP
4.00M
4.12%
-356.63K
-8.19%
Jun 30, 2025
Kotler (Kevin)
3.72M
3.83%
-1.01M
-21.37%
Feb 12, 2024
Vivo Capital, LLC
2.68M
2.76%
--
--
Jun 30, 2025
Wealth Effects LLC
2.35M
2.43%
-14.30K
-0.60%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco Pharmaceuticals ETF
2.75%
Innovator IBD 50 Fund ETF
2.64%
iShares Neuroscience and Healthcare ETF
2.45%
SPDR S&P Pharmaceuticals ETF
1.82%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.37%
iShares U.S. Pharmaceuticals ETF
0.55%
Janus Henderson Small/Mid Cap Growth Alpha ETF
0.36%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.19%
JPMorgan Fundamental Data Science Small Core ETF
0.16%
Invesco Nasdaq Biotechnology ETF
0.15%
View more
Invesco Pharmaceuticals ETF
Proportion2.75%
Innovator IBD 50 Fund ETF
Proportion2.64%
iShares Neuroscience and Healthcare ETF
Proportion2.45%
SPDR S&P Pharmaceuticals ETF
Proportion1.82%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.37%
iShares U.S. Pharmaceuticals ETF
Proportion0.55%
Janus Henderson Small/Mid Cap Growth Alpha ETF
Proportion0.36%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.19%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.16%
Invesco Nasdaq Biotechnology ETF
Proportion0.15%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
